Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Pivotal data set the stage for slightly delayed US accelerated approval filing.
Global data are in the same ballpark as Chinese results presented earlier this year.
The latest projects newly into human trials include BNT3212.
But results come from a curated dataset, with no in-trial comparator.
A common mutation comes into play for PRMT5 inhibition.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
